Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Hanyu Completes $72 Million Round for Cardiovascular Devices

publication date: Aug 14, 2020

Shanghai Hanyu, a cardiovascular medical device company, completed a $72 million Series D round financing. The round was co-led by Highlight Capital, CITIC Private Equity Funds Management, and Yingke PE. Founded in 2016, Hanyu's core product is Valve Clamp, a minimally invasive mitral valve interventional device used to treat mitral valve regurgitation diseases. Valve Clamp is the first China-developed mitral valve device to start clinical trials. Hanyu expects Valve Clamp will be the second mitral valve repair system marketed in China after Abbott’s MitraClip. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital